Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough? Conference Paper
| Authors: | Woods, R. S. R.; Fitzgerald, C. W. R.; Valero, C.; Lopez, J.; Morris, L. G. T.; Cohen, M. A.; Wong, R. J.; Patel, S. G.; Ghossein, R. A.; Tuttle, R. M.; Shaha, A. R.; Shah, J. P.; Ganly, I. |
| Title: | Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough? |
| Conference Title: | 42nd Annual Meeting of the American Association of Endocrine Surgeons |
| Abstract: | Background: The tall cell variant of papillary thyroid carcinoma has traditionally been treated more aggressively than classic papillary thyroid carcinoma. However, this may not be justified in patients with T1/T2 tall cell variant node-negative tumors. Methods: We evaluated well-differentiated thyroid cancers treated surgically between 1985 and 2015 at our institution. We compared patients undergoing lobectomy for node-negative T1/T2 tall cell variant tumors with the same cohort with classic papillary thyroid carcinoma. Patients who underwent early planned completion thyroidectomy were excluded. Tall cell variant tumors were defined as those with ≥30% tall cells. Survival and recurrence outcomes were determined by the Kaplan-Meier method and groups compared using the log-rank test. Results: Thyroid lobectomy was performed for T1/T2 N0X disease in 70 (15%) tall cell cases and 429 (23%) classic papillary thyroid carcinoma cases. There was no significant difference in 10-year overall survival (P =.56) or locoregional recurrence-free probability (P =.52). Disease-specific survival and local or central nodal recurrence-free probability were 100% in both groups. In 9 papillary thyroid carcinoma cases, subsequent contralateral lobe tumors developed, and in 5, lateral neck metastases developed. No recurrences were seen in the tall cell group. Conclusion: T1 node-negative tumors with tall cell histology can be satisfactorily managed with thyroid lobectomy, with equivalent oncological outcomes to classic papillary thyroid carcinoma. © 2022 Elsevier Inc. |
| Keywords: | adult; cancer survival; controlled study; human tissue; cancer surgery; retrospective studies; major clinical study; overall survival; histopathology; cancer recurrence; patient selection; conference paper; outcome assessment; treatment indication; neoplasm recurrence, local; carcinoma, papillary; cohort analysis; pathology; retrospective study; tumor recurrence; thyroidectomy; surgery; thyroid neoplasms; cancer classification; papillary carcinoma; lobectomy; thyroid papillary carcinoma; thyroid tumor; disease specific survival; recurrence free survival; neck metastasis; procedures; oncological parameters; hemithyroidectomy; humans; human; male; female; thyroid cancer, papillary |
| Journal Title | Surgery |
| Volume: | 173 |
| Issue: | 1 |
| Conference Dates: | 2022 May 22-24 |
| Conference Location: | Cleveland, OH |
| ISBN: | 0039-6060 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-01-01 |
| Start Page: | 246 |
| End Page: | 251 |
| Language: | English |
| DOI: | 10.1016/j.surg.2022.05.045 |
| PUBMED: | 36257862 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Conference Paper -- Export Date: 3 January 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work